Biohaven Pharmaceutical Holding Gross Profit 2016-2021 | BHVN

Biohaven Pharmaceutical Holding annual/quarterly gross profit history and growth rate from 2016 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Biohaven Pharmaceutical Holding gross profit for the quarter ending September 30, 2021 was $0.110B, a 721.36% increase year-over-year.
  • Biohaven Pharmaceutical Holding gross profit for the twelve months ending September 30, 2021 was $0.242B, a 1063.84% increase year-over-year.
  • Biohaven Pharmaceutical Holding annual gross profit for 2020 was $0.046B, a INF% increase from 2019.
  • Biohaven Pharmaceutical Holding annual gross profit for 2019 was $0B, a NAN% decline from 2018.
  • Biohaven Pharmaceutical Holding annual gross profit for 2018 was $0B, a NAN% decline from 2017.
Biohaven Pharmaceutical Holding Annual Gross Profit
(Millions of US $)
2020 $46
2019 $
2018 $
2017 $
2016 $
2015 $
Biohaven Pharmaceutical Holding Quarterly Gross Profit
(Millions of US $)
2021-09-30 $110
2021-06-30 $76
2021-03-31 $31
2020-12-31 $25
2020-09-30 $13
2020-06-30 $7
2020-03-31 $1
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.783B $0.064B
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90